SG11201803642WA - Bacteria-based protein delivery - Google Patents
Bacteria-based protein deliveryInfo
- Publication number
- SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- basel
- rule
- november
- domains
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195493 | 2015-11-19 | ||
| PCT/EP2016/078087 WO2017085235A1 (en) | 2015-11-19 | 2016-11-17 | Bacteria-based protein delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803642WA true SG11201803642WA (en) | 2018-06-28 |
Family
ID=54697465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803642WA SG11201803642WA (en) | 2015-11-19 | 2016-11-17 | Bacteria-based protein delivery |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11702663B2 (sl) |
| EP (1) | EP3377634B1 (sl) |
| JP (1) | JP6937752B2 (sl) |
| KR (1) | KR102689434B1 (sl) |
| CN (1) | CN108884466B (sl) |
| AU (1) | AU2016355975B2 (sl) |
| CA (1) | CA3005380A1 (sl) |
| CY (1) | CY1123654T1 (sl) |
| DK (1) | DK3377634T3 (sl) |
| EA (1) | EA039922B1 (sl) |
| ES (1) | ES2830251T3 (sl) |
| HK (1) | HK1256138A1 (sl) |
| HR (1) | HRP20201792T1 (sl) |
| HU (1) | HUE051184T2 (sl) |
| IL (1) | IL259050B2 (sl) |
| LT (1) | LT3377634T (sl) |
| PL (1) | PL3377634T3 (sl) |
| PT (1) | PT3377634T (sl) |
| RS (1) | RS61046B1 (sl) |
| SG (1) | SG11201803642WA (sl) |
| SI (1) | SI3377634T1 (sl) |
| WO (1) | WO2017085235A1 (sl) |
| ZA (1) | ZA201803901B (sl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071182A1 (en) | 2012-11-01 | 2014-05-08 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
| LT3145946T (lt) * | 2014-05-21 | 2019-11-25 | Univ Basel | Baltymo pernešimas, panaudojant bakterijas |
| KR102461443B1 (ko) | 2015-07-13 | 2022-10-31 | 피벗 바이오, 인크. | 식물 형질 개선을 위한 방법 및 조성물 |
| EP3903813A1 (en) | 2015-11-19 | 2021-11-03 | Universität Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| MX2019007264A (es) | 2016-12-20 | 2019-11-18 | Univ Basel | Suministro de proteinas basado en bacterias con virulencia atenuada. |
| MX2020004343A (es) | 2017-10-25 | 2021-01-08 | Pivot Bio Inc | Métodos y composiciones para mejorar microbios modificados que fijan nitrógeno. |
| WO2022087856A1 (zh) * | 2020-10-26 | 2022-05-05 | 南京吉芮康生物科技研究院有限公司 | 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用 |
| CA3195544A1 (en) * | 2020-10-27 | 2022-05-05 | T3 Pharmaceuticals Ag | Bacteria based protein delivery |
| IL305974A (en) * | 2021-03-25 | 2023-11-01 | T3 Pharmaceuticals Ag | Pharmaceutical combinations for cancer treatment |
| CN117362451B (zh) * | 2023-12-04 | 2024-03-08 | 北京质肽生物医药科技有限公司 | 一种包含tev蛋白酶的融合蛋白、制备方法及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| US6596509B1 (en) * | 1998-07-10 | 2003-07-22 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type III secretion systems |
| AU2001294834A1 (en) | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| AU2002312778A1 (en) * | 2001-03-26 | 2002-10-08 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| FR2862312B1 (fr) * | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| US8357373B2 (en) | 2005-10-04 | 2013-01-22 | Ludwig Institute For Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) * | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| WO2009115531A2 (en) | 2008-03-17 | 2009-09-24 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| US8524220B1 (en) * | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| CN105764926A (zh) * | 2013-09-24 | 2016-07-13 | 梅迪塞纳医疗股份有限公司 | 白介素-4受体结合融合蛋白及其应用 |
| US10143743B2 (en) * | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| LT3145946T (lt) * | 2014-05-21 | 2019-11-25 | Univ Basel | Baltymo pernešimas, panaudojant bakterijas |
| EP3903813A1 (en) | 2015-11-19 | 2021-11-03 | Universität Basel | Virulence attenuated bacteria for treatment of malignant solid tumors |
| MX2019007264A (es) | 2016-12-20 | 2019-11-18 | Univ Basel | Suministro de proteinas basado en bacterias con virulencia atenuada. |
-
2016
- 2016-11-17 EP EP16825704.6A patent/EP3377634B1/en active Active
- 2016-11-17 KR KR1020187016715A patent/KR102689434B1/ko active IP Right Grant
- 2016-11-17 ES ES16825704T patent/ES2830251T3/es active Active
- 2016-11-17 CN CN201680079453.5A patent/CN108884466B/zh active Active
- 2016-11-17 PL PL16825704T patent/PL3377634T3/pl unknown
- 2016-11-17 PT PT168257046T patent/PT3377634T/pt unknown
- 2016-11-17 AU AU2016355975A patent/AU2016355975B2/en active Active
- 2016-11-17 EA EA201890914A patent/EA039922B1/ru unknown
- 2016-11-17 RS RS20201344A patent/RS61046B1/sr unknown
- 2016-11-17 DK DK16825704.6T patent/DK3377634T3/da active
- 2016-11-17 LT LTEP16825704.6T patent/LT3377634T/lt unknown
- 2016-11-17 US US15/773,526 patent/US11702663B2/en active Active
- 2016-11-17 IL IL259050A patent/IL259050B2/en unknown
- 2016-11-17 CA CA3005380A patent/CA3005380A1/en active Pending
- 2016-11-17 SI SI201630974T patent/SI3377634T1/sl unknown
- 2016-11-17 HU HUE16825704A patent/HUE051184T2/hu unknown
- 2016-11-17 WO PCT/EP2016/078087 patent/WO2017085235A1/en active Application Filing
- 2016-11-17 SG SG11201803642WA patent/SG11201803642WA/en unknown
- 2016-11-17 JP JP2018526175A patent/JP6937752B2/ja active Active
-
2018
- 2018-06-12 ZA ZA2018/03901A patent/ZA201803901B/en unknown
- 2018-11-28 HK HK18115219.3A patent/HK1256138A1/zh unknown
-
2020
- 2020-11-05 CY CY20201101044T patent/CY1123654T1/el unknown
- 2020-11-09 HR HRP20201792TT patent/HRP20201792T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE051184T2 (hu) | 2021-03-01 |
| IL259050A (en) | 2018-07-31 |
| EP3377634A1 (en) | 2018-09-26 |
| IL259050B1 (en) | 2023-11-01 |
| BR112018009782A8 (pt) | 2019-02-26 |
| RS61046B1 (sr) | 2020-12-31 |
| KR20180081798A (ko) | 2018-07-17 |
| DK3377634T3 (da) | 2020-11-16 |
| EA201890914A1 (ru) | 2018-12-28 |
| SI3377634T1 (sl) | 2021-01-29 |
| PL3377634T3 (pl) | 2021-03-08 |
| AU2016355975A1 (en) | 2018-05-10 |
| ES2830251T3 (es) | 2021-06-03 |
| EA039922B1 (ru) | 2022-03-28 |
| HK1256138A1 (zh) | 2019-09-13 |
| US20190194670A1 (en) | 2019-06-27 |
| CN108884466A (zh) | 2018-11-23 |
| US11702663B2 (en) | 2023-07-18 |
| ZA201803901B (en) | 2019-04-24 |
| LT3377634T (lt) | 2020-12-28 |
| KR102689434B1 (ko) | 2024-07-29 |
| IL259050B2 (en) | 2024-03-01 |
| EP3377634B1 (en) | 2020-08-12 |
| CA3005380A1 (en) | 2017-05-26 |
| WO2017085235A1 (en) | 2017-05-26 |
| HRP20201792T1 (hr) | 2020-12-25 |
| CN108884466B (zh) | 2022-06-03 |
| AU2016355975B2 (en) | 2022-12-08 |
| BR112018009782A2 (pt) | 2018-11-06 |
| JP2019500027A (ja) | 2019-01-10 |
| CY1123654T1 (el) | 2022-03-24 |
| JP6937752B2 (ja) | 2021-09-22 |
| PT3377634T (pt) | 2020-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201407343XA (en) | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201408051VA (en) | Cho expression system | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |